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Introduction
Conserved nucleotide substitutions that occur during evolution are considered to be polymorphisms when the prevalence of the rare or minor allele reaches 0.01 (1%) (1) . Repetitive DNA sequences are composed of multiple consensus motifs. These consensus motifs may be short (di-and trinucleotides) or long nucleotides) and are arranged in tandem array. Concatenations of these consensus motifs form minisatellite or microsatellite regions that may be tens, hundreds, or thousands of nucleotides in length. Mutational pressures that lengthen or shorten these reiterated sequences spawn multiallelic, variable (or hypervariable) tandem repeat (VTR) polymorphisms (2) . These conserved DNA-polymorphisms may be silent or they may encode a structural or functional change.
Inheritance of mutations in certain critical genes predispose to various types of family cancer syndrome. These include germ line mutations in p53, BRCA-1, Rb, MCC, MSH-2, and WT-1 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . The identification, isolation, and cloning of these genes has resulted in increased knowledge of inheritance of these syndromes. Overt predisposition to disease occurs when a germ line mutation in a tumor suppressor gene is inherited. Alternately, it is proposed that more subtle predisposition to common adult cancers may result from inheritance of specific genetic polymorphisms. These may alter susceptibility in conjunction with certain environmental exposures.
To test this hypothesis several molecular epidemiologic lung and breast cancer case-control studies have been performed . This report focuses on those studies that have examined possible associations between polymorphisms at the H-ras-1 and p53 gene loci and lung cancer and breast cancer predisposition.
The p53 gene is functionally characterized as a tumor suppressor gene (10) . Somatic mutations (primarily nucleotide substitutions) of this gene have been detected in diverse human cancer types (36) and inheritance of germ line mutations predispose to breast, colon, and brain cancers (37, 38) . The role of p53 is to prevent tissue overgrowth; one mechanism operates through abrogation of cells with damaged genomes. Homeostatic controlling functions, even in the presence of already severely damaged cells that are being driven by activated protooncogenes (oncogenes) may be maintained by a fully functional p53 protein. The role of p53 in the life cycle of the cell is becoming increasingly well understood. The p53 protein has been shown to have broad functionality in cellular processes. These include cell-cycle control, DNA repair, differentiation, genomic plasticity, and apoptosis (programmed cell death) (39) (40) (41) .
Ten genetic polymorphisms that have been described for p53 are cataloged in Table 1 (21, (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) . Three of the five nucleotide substitution polymorphisms are silent, conferring no change in amino acid sequence, and two cause amino acid substitutions. At codon 47 a proline to serine substitution was found in 0 of 69 Caucasians and 3 of 32 (3 of 64 alleles, 0.047) African Americans; results of in vitro experiments that used a construct of this allele containing a luciferase reporter gene indicated that this polymorphism does not interfere with growth-suppressor activity (21) . At codon 72 a G<-*C transition, recognized by Acc II and several isoschizomers (Bsp50-1, BstUI, Bshl2361, MvnI, and ThaI), accounts for an arginine*-+proline amino acid substitution. The reported allelic frequencies for this polymorphism are given in Table 1 and vary with respect to race. This polymorphism has been investigated in several case-control studies of lung cancer, as well as breast, colon, stomach, and bladder cancers (13) (14) (15) (16) (17) (18) (19) (20) . Five of the ten p53 polymorphisms occur in intronic sequences. Three of these are revealed by restriction digestion in introns 1, 6, and 7 (46, 48, 49, 51, 54) . One polymorphism is a six allele VTR in intron 1 (55) . In intron 3 there is a biallelic 16 bp insertion/deletion (56 (61) reported that individuals who inherited rare alleles were at increased risk of cancer. In the intervening years, numerous investigators have tried to replicate these findings in specific cancer types through case-control studies (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) and family studies (32, 33) , with varying success.
This report is a metaanalysis that formally summarizes the molecular epidemiologic data for the associations of both p53 and H-ras-1 polymorphisms with risk of either breast cancer or lung cancer.
Methods

Study Subject
Subjects were either lung or breast cancer cases and controls who participated in 21 reported studies (24, 34) . Samples of similar migration characteristics are reanalyzed by migration in adjacent lanes (24, 25) or in the same lane (34) . Concatameric DNA plasmids consisting of 30 to 50 bp increments (DNA ladders) are used for accurate fragment size determination (26) . Together with the use of Msp IlHpa II, these improvements yield highly consistent and accurate determination of H-ras-1 allotype.
Determination of p53 Codon 72 Polymorphism
The polymerase chain reaction and restriction digestion of polymerase chain reaction (PCR) amplicons are used to determine this polymorphism. Using this basic strategy, researchers have applied two methods. First, a simple restriction digestion of an amplified product has been used (14) . Alternately, a 3' mismatch primer incorporating a de novo Acc II restriction site has been used to control for complete digestion and concomitant allelic misclassification (13) . In the latter method the following primers were used: a) forward= 5'CCCCAACCCCAGCCCCCTAGCAG AGACCTGTGGGACGCG3', b) reverse 5'TGTCATCTTCTGTCCCTTCCC AGA3', and c) reverse 5'ACACCGGCGG CCCCTGCACCA3'. Primers 1 and 2 were first used to generate a 397 bp template. A heminested PCR using primers 1 and 3 was then used to generate fragments for restriction analysis. Restriction enzymes Acc II (US Biochemicals, Cleveland, OH; no longer available; see "Introduction" for a listing of isoschizomers) and Bsp50-I (Stratagene, Lajolla, CA) were used to distinguish between the arginine (restriction site present) and proline (restriction site absent) alleles of p53. Agarose gel electrophorsis (2%), with ethidium bromide detection, was used to separate the restriction fragments and PCR products.
Statistical Analyses
To test whether the distribution of genotypes was the same for cases and controls within a given study, a chi-sqaure statistic with 2 degrees of freedom was used (64) . Odds ratios from multiple studies were combined to form a summary odds ratio using the Mantel-Haenszel method (65) .
For case-control studies of p53 polymorphisms, the gene frequency for the proline variant was estimated separately for the cases and controls using the observed number of individuals for each of three genotypes (proline homozygotes, arginine homozygotes, and heterozygotes). This gene frequency in turn was used to calculate the expected numbers of individuals for the three genotypes in each group based on the Hardy-Weinberg law of equilibrium. To test whether either the cases or the controls were in equilibrium, a chi-square goodness of fit test was used (66) . The Breslow-Day test was used to assess homogeneity of odds ratios across various studies (67) . Population attributable risk (PAR) for inheritance of H-ras-1 rare alleles in lung cancer and breast cancer was determined according to Kuritz and Landis (68) . For H-ras-1, numbers of subjects in Tables 2 to 4 represent numbers of individuals; however, chisquare tests were performed on allelic distributions and gene frequencies.
Results
Lung Cancer Studies
Inheritance ofH-ras-1 Rare Alleles. Six case-control studies in three laboratories have examined the risk of lung cancer that can be attributed to inheritance of rare Hras-1 alleles. Two of these studies were performed in the United Kingdom and used Pvu II for allele characterization (22, 23 Table 2 ). In the United States, Sugimura et al. (24) and Weston et al. (25) performed three independent studies of lung cancer risk and inheritance of rare H-ras-1 alleles [also, Weston et (Table 3) . However, the proline variant was the major allele in African Americans compared to Japanese, Caucasians, and Mexican Americans where the arginine allele was found to be most prevalent (Tables 1, 3 ) (13) (14) (15) (16) (17) (18) (19) (20) . Among Japanese, Kawajiri et al. (14) considered allelic distribution as it pertained to the Hardy-Weinberg equilibrium. Although the arginine/proline allelic frequencies were not different between cases and controls (arginine allele 0.653 in controls, 0.645 in cases), among controls the allelic distribution was in Hardy-Weinberg equilibrium whereas in cases it was not. In cases there was an underrepresentation of heterozygotes and an overrepresentation of proline homozygotes (p<0.005, Table 3 ). In contrast, Murata et al. (19) examined the relationship between the codon 72 polymorphism, lung cancer, and tobacco smoking in a Japanese population but reported an association of p53 with tendency to smoke tobacco, where the arginine allele was elevated in nonsmoking cancer patients (chi-square = 13.5, p< 0.001). This association was, in turn, the driving force behind the subsequent observation that arginine homozygotes were in excess among nonsmoking lung cancer cases (chisquare = 10.9, p < 0.01) ( 19) . Jin (20) .
Birgander et al. (17) have extended these p53 studies by considering inheritance of pairwise haplotypes of three polymorphic p53 loci. The loci of interest were the codon 72 nucleic acid base substitution, the intron three 16 bp insertion (A2)/deletion (Al), and the intron 6 Msp I RFLP. Swedish Saamis were found to have the highest frequency of the codon 72 arginine variant so far described (0.830); evidence from these studies did not support the hypothesis that the codon 72 proline variant is a risk factor for lung cancer. Nor did the data suggest that the other p53 polymorphisms were independent lungcancer risk factors. However, the proportion of proline/intron three Al to proline/intron three A2 haplotypes was found to be almost twice as frequent (1.78-fold) in lung cancer cases as in controls (p= 0.032) (17) . The data suggest that the proline/intron three Al haplotype is a lung-cancer risk factor. The same authors have also shown that this haplotype may be a risk factor for colon cancer (16) .
Breast Cancer Studies
Inheritance ofH-ras-1 Rare Alleles. For breast cancer, nine studies have been reported from eight laboratories between 1986 and 1993 (Table 4 ). All studies indicate increased RR of breast cancer associated with inheritance of H-ras-l rare alleles. The RR values ranged from 1.2 to 6.5; five studies were highly significant; two studies were of marginal significance, and two studies did not reach significance. Overall there was a highly significant risk of breast cancer associated with inheritance of H-ras-1 rare alleles (RR= 2.7, 95% CI = 2.1-3.4, p = 0.000, n = 1,631; Table 4 ; (Figure 2 ). The Breslow-Day test for homogeneity across these studies proved to be almost significant (p = 0.055); therefore, the data were investigated further. Studies on breast cancer used a range of restriction enzymes for allelic classification (Figure 2 , legend). The enzyme likely to yield the least accurate results, BamHI, was used in the study that found the strongest association between breast cancer risk and inheritance of rare H-ras-1 alleles (27) . Although the authors used Msp IlHpa II to confirm rare alleles, when this study was omitted from the analysis, the overall combined data still yielded a statistically significant (68) . Two studies examined inheritance of rare alleles in families with a high incidence of breast cancer. One study that examined three Icelandic families found no rare H-ras-1 alleles in any of 10 affected members (32) . In a second study, in the United States, 12 breast cancer families were studied (33) . Seven of these twelve families had members who carried rare H-ras-1 alleles. However, no evidence was found to support the hypotheses that breast cancer cosegregated with either rare or common H-ras-1 alleles (33) .
Inheritance ofPolymorphism in p53. Very limited data yet exist on the potential association of p53 polymorphisms and breast cancer risk. A single study by Kawajiri et al. (14) determined the allelic frequencies of the p53 codon 72 polymorphism in breast cancer cases (n= 93) and controls (n = 347). The overall frequencies for the proline variant were 0.328 for cases and 0.347 for controls. These data do not indicate that inheritance of this p53 polymorphism is a breast cancer risk factor. Furthermore, Kawajiri et al. reported the allelic distributions for cases and controls to be similar (chi-square = 3.18, p= 0.2, degrees of freedom = 2), and both cases and control populations were in Hardy-Weinberg equilibrium (14) .
Germ line mutations in the p53 gene have a role in cancer family syndromes that include breast cancer as a feature (38 (77) . Only recently has it been questioned whether common polymorphisms in the p53 gene might have a role as a cancer risk factor. At least 10 p53 polymorphisms have been identified to date ( Table 1 ). The codon 72 arginine/proline polymorphism has been most extensively studied, in part because it has a high prevalence. Convincing evidence that the codon 72 polymorphism has a role in cancer etiology remains to be documented. Most recently, haplotyping studies have suggested that certain p53 polymorphisms may be a marker for (that is, in linkage disequilibrium with) another chromosome 17p gene responsible for disease risk (16, 17) .
Little evidence has been provided here to implicate p53 polymorphisms in human cancer risk (13) (14) (15) (16) (17) (18) (19) (20) . Other studies that examined molecular mechanistic questions using specific genetic constructs have also failed to indicate disease risk (21) . The most recent studies that identify highly specific p53 haplotypes as cancer risk factors require further investigation (16, 17) . These investigations can usefully be pursued along molecular epidemiological lines as well as cell and molecular lines in the laboratory.
Although little evidence of breast and lung cancer risk is evident from current p53 polymorphism studies, reports exist to implicate p53 polymorphisms in ovarian cancer. A description has appeared in the literature that implicates the intron 3,16 bp insertion with risk of ovarian cancer (RR= 8.6, 95% Cl 3.0-25.2) (57).
Conclusions
The published studies (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) that have examined an association of inheritance of the H-ras-I VTR with breast cancer are remarkably consistent. All find a positive association and most are statistically significant ( Figure 2 ). Fewer studies of lung cancer point to a similar trend, indicating inheritance of H-ras-1 rare alleles to be a significant risk factor.
Studies of polymorphisms in p53 are currently less well developed (13) (14) (15) (16) (17) (18) (19) (20) (21) .
Most have focused on the codon 72 polymorphism, for which the weight of evidence appears to support the null hypothesis. However, considerable possibilities exist given the pivotal role of this gene in neoplasia and the number of polymorphisms so far reported (21, (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) . Recent studies have led to consideration of estimated haplotypes (16, 17) . New directions in our laboratory have focused on the absolute determination of haplotypes in diploid genomes using available molecular biologic technologies (78) .
NOTE ADDED IN PROOF: For H-ras-1 an interaction between rare alleles and mutated BRCA-1 has been reported (80) . In addition, two reports have been published that indicate a specific p53 haplotype, consisting of a constellation of 3 polymorphisms (intron 3, exon 4, and intron 6) and designated 1-2-1, is a breast cancer risk factor (78, 81) .
